Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-813160 phase 2a study in type 2 diabetes mellitus with diabetic kidney disease and residual macroalbuminuria
2012-005093-54Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetic glomerulosclerosis and type 2 diabetes mellitus (T2DM) comparing BMS-813160 with Placebo (2 arms). Primary endpoint: Percent change from baseline in urinary albumin-to-creatinine ratio. Started May 2013; status: terminated.
02
Drugs
BMS-813160
03
Conditions
diabetic glomerulosclerosistype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2012-005093-54.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005093-54.